CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS
CDC/NIH VIRAZOLE HANTAVIRUS STUDY HAS ENROLLED 130-140 PATIENTS, close to the target enrollment for the study of 150, Centers for Disease Control & Prevention Drug Service Head John Becher said June 30. The open-label trial began enrollment in June 1993, shortly after the outbreak of the virus in May, and is being administered by the National Institutes of Health and CDC in the "Four Corners" area of Colorado, Arizona, New Mexico and Utah. The trial protocol was designed by FDA. CDC is purchasing the study medication, a parenteral formulation of Virazole (ribavirin) from ICN's Viratek subsidiary.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth